Page 4 - T Cell News Today

The effect of Interleukin-24 (IL-24) on CSCs and CAR-T cell therapy.

Researchers assessed Smith (Sm)-specific regulatory T cells (Tregs) efficacy in halting lupus nephritis (LN) by engineering and testing epitope-targeted Tregs for systemic lupus erythematosus (SLE) treatment.

A study led by Brazilian researchers shows that people who have had zika run a higher risk of subsequently having severe dengue and being hospitalized.

As the HIV virus glides up outside a human cell to dock and possibly inject its deadly cargo of genetic code, there's a spectacularly brief moment in which a tiny piece of its surface snaps open to begin the process of infection.

A study led by UMass Chan Medical School viral immunologists Liisa Selin, MD, PhD, and Anna Gil, PhD, discovered similarities in immune system dysfunction as a potential biomarker among people living with long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Most approved gene therapies today, including those involving CRISPR-Cas9, work their magic on cells removed from the body, after which the edited cells are returned to the patient.

Study evaluates senolytic CAR T-cell therapy targeting uPAR-positive cells in aged mice, showing its effectiveness in mitigating age-related metabolic dysfunction and offering a potential long-lasting treatment for aging-associated conditions.

NewsMedical speaks with Chao Ma, Ph.D. a Research Assistant Professor at New York University Tandon School of Engineering, ahead of his presentation at SLAS 2024.

The potential benefits of CAR T-cell therapies still far outweigh the risks

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.